MYELODYSPLASTIC SYNDROMES

This early-phase study tests a new treatment for adults with acute myeloid leukemia or myelodysplastic syndrome who still have detectable cancer cells after standard therapy. The treatment uses the patient's own blood cells, which are armed with a special antibody to better targe…

This early-stage study tests a new drug, SX-682, alone or with another drug (decitabine) in people with myelodysplastic syndrome (MDS), a bone marrow disorder. The main goal is to find a safe dose and check for side effects. About 151 adults who have not responded to prior treatm…

This study tests whether giving two drugs, decitabine and filgrastim, after a stem cell transplant can help prevent blood cancers like AML and MDS from coming back in children and young adults. About 37 participants will receive the drug combination for up to 6 cycles. The main g…

This early-phase study tests whether adding an experimental drug (defactinib) to an approved oral treatment (decitabine/cedazuridine) is safe and tolerable for people with high-risk myelodysplastic syndromes, certain acute myeloid leukemias, or chronic myelomonocytic leukemia. Al…

This study tests a stem cell transplant that removes certain immune cells to prevent graft-versus-host disease, a common complication. The goal is to help patients with inherited bone marrow failure recover their immune system faster and avoid severe infections. About 48 particip…

This early-stage study tests whether giving extra immune cells (gamma delta T-cells) after a half-matched bone marrow transplant can help kill cancer cells while reducing the risk of graft-versus-host disease. About 38 adults with certain blood cancers or pre-cancers will take pa…

This study tests a low-dose weekly combination of two FDA-approved drugs, decitabine and venetoclax, for people with bone marrow cancers like MDS, AML, and CMML. The goal is to see if this gentler schedule can control the disease while causing fewer treatment delays or interrupti…

This study tests whether giving a drug combination called DEC-C early to people with myelodysplastic syndromes (MDS) who still have signs of disease after a stem cell transplant can lower the chance of the cancer coming back. About 209 participants will be checked for leftover di…

This early-phase study tests a new drug called danvatirsen, first alone and then combined with venetoclax, in 38 adults with relapsed or treatment-resistant acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if the treatment is safe and can shrink…

This study tests a drug called elritercept in adults with a bone marrow disease called myelodysplastic syndromes (MDS) who need regular red blood cell transfusions. The main goal is to see if the drug can help patients go at least 8 weeks without a transfusion. About 225 particip…

This study tests whether a new way of giving three drugs (ATG, tacrolimus, and methotrexate) can prevent graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers like leukemia. About 29 adults aged 18-60 will take part. The goal is to see if t…

This study tests a new drug called AND017 for anemia caused by a bone marrow condition called lower-risk myelodysplastic syndromes (MDS). About 63 adults with MDS who need few or no blood transfusions will receive different doses of AND017 to see if it can raise hemoglobin levels…

This study tests a drug called pacritinib in people aged 12 and older with myelodysplastic syndromes (MDS) or related blood cancers. The goal is to find the best dose and see if it can shrink or control the disease. Participants take capsules twice daily for up to 8 years, with r…

This early-stage trial tests a new treatment called MNV-201 for people with a low-risk form of myelodysplastic syndrome (MDS), a bone marrow disorder that causes low blood counts. The therapy uses the patient's own blood stem cells, boosted with mitochondria from donated placenta…

This study tests a stem cell transplant method for people with blood cancers like AML and MDS. Participants receive a reduced-intensity chemo regimen followed by donor stem cells and drugs to prevent graft-versus-host disease. The goal is to improve survival at 100 days and beyon…

This early-phase study tests a new oral drug, GLB-001, in about 48 adults whose acute myeloid leukemia or high-risk myelodysplastic syndromes have returned or stopped responding to standard therapy. The main goals are to check safety, find the best dose, and see if the drug can h…

This study looks at how the cancer drug ASTX727 (decitabine and cedazuridine) works in people with moderate or severe liver problems. About 27 adults with certain blood cancers or solid tumors will take the drug for up to 8 weeks. The goal is to understand how the liver affects t…

This study tests whether alternating two different drug combinations can help control higher-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). About 60 adults whose cancer has not responded to or has returned after standard treatment will receive one…

This early-phase study tests a specially engineered donor cell product called Orca-Q in 300 people with blood cancers like leukemia or myelodysplastic syndromes who need a stem cell transplant. The goal is to see if this new graft is safe and helps the body accept the donor cells…

This study tests whether a tailored exercise program combined with a vitamin-like supplement (called NR) can improve muscle strength and fitness in teens and young adults who had a bone marrow transplant for leukemia or other blood disorders. About 80 participants will be randoml…

This study tests a new drug, enzomenib, in adults with acute leukemia and other blood cancers that have come back or not improved with standard treatments. The goal is to find a safe dose and see if the drug can shrink or control the cancer. About 606 people will take part in thi…

This study tests two different drug combinations to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body after a stem cell transplant. About 400 adults with blood cancers like leukemia or lymphoma will receive either thymogl…

This early-phase study tests an experimental oral drug called BH-30236 in adults whose acute myeloid leukemia or high-risk myelodysplastic syndrome has returned or not responded to prior treatments. The trial first finds a safe dose, then tests the drug alone or with another medi…

This early-phase study tests a new drug called MGD024 in about 130 adults with certain blood cancers (like leukemia or lymphoma) that have not improved with standard treatments or have returned. The main goal is to find the safest dose and understand side effects. Participants re…

This study tests whether adding hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) to standard stem cell transplant preparation is safe and helps recovery. It includes adults up to age 75 with certain blood cancers or bone marrow disorders. The goal is to …

This study tests an experimental drug called CTX-712 in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have come back or not responded to prior treatments. The goal is to find a safe dose and see if the drug can shrink or control the ca…

This study tests a combination of two drugs, luspatercept and EPO, for people with a low-risk form of myelodysplastic syndrome (MDS) that does not involve ring sideroblasts. Participants must have already tried and failed EPO alone or have high EPO levels making them ineligible. …

This study tests whether adding interferon-γ to donor immune cells can help adults whose acute myeloid leukemia or myelodysplastic syndrome has returned after a stem cell transplant. About 45 participants will receive the combination and be followed for one year to see if the can…

This early-phase study tests whether giving special immune cells (CIML NK cells) after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like acute myeloid leukemia. About 15 participants will receive the cells along with a drug called IL-2. T…

This study tests a drug called olutasidenib in people with certain early blood conditions (CCUS, lower-risk MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if the drug can control the disease and is safe. About 15 participants will take the drug and be mon…

This early-phase study tests whether adding the drug momelotinib to standard treatment (azacitidine) can better control rare blood cancers like chronic myelomonocytic leukemia and chronic neutrophilic leukemia. About 18 adults will take the combination for up to 24 months. The go…

This early-phase trial tests a new treatment called Orca-T for people with advanced blood cancers (like leukemia) who need a stem cell transplant from a partially matched donor. The goal is to see if Orca-T can prevent serious complications such as graft failure, severe graft-ver…

This study is testing whether a cord blood transplant can help children and young adults (up to age 26) with blood cancers like leukemia and lymphoma. The transplant uses stem cells from donated cord blood to replace damaged bone marrow. The main goal is to see how many patients …

This study tests an experimental drug called BGB-11417 for people with acute myeloid leukemia (AML) and related bone marrow disorders. The drug works by blocking a protein that helps cancer cells survive. The trial will find the safest dose and see if the drug, alone or with anot…

This study tests a new drug called DISC-0974 for people with myelofibrosis or myelodysplastic syndrome (MDS) who also have anemia. The goal is to see if the drug is safe and can help reduce or stop the need for blood transfusions. About 150 adults will take part in this early-pha…

This study tests whether using stem cells from both a half-matched family donor and a cord blood donor can improve survival without cancer returning. It is for people with certain high-risk blood cancers like leukemia or myelodysplastic syndromes. The approach aims to control the…

This study tests whether statins, common cholesterol-lowering drugs, can reduce inflammation and slow the progression of two blood disorders: CCUS and lower-risk MDS. These conditions can lead to more serious blood cancers or heart problems, and there are no approved treatments t…

This study is for people with myelodysplastic syndromes (MDS) whose disease has returned or not responded to standard treatment. Researchers are testing a combination of two drugs, leflunomide and decitabine, to find the safest and most effective doses. The goal is to control the…

This early-stage trial tests a special type of immune cell (CIML NK cells) combined with a low dose of IL-2 in people whose blood cancer (like AML or MDS) came back after a stem cell transplant. The goal is to find a safe dose and see if it can put the cancer back into remission.…

This study tests a drug called momelotinib in 80 adults with low-risk myelodysplastic syndromes who have anemia. The goal is to see if it can help them need fewer red blood cell transfusions. Participants will receive different doses to find the safest and most effective one.

This study tests an oral drug (ASTX030) that combines two medicines to treat certain blood cancers like myelodysplastic syndromes and acute myeloid leukemia. The goal is to see if taking a pill works as well as getting a shot, with fewer trips to the clinic. About 316 adults will…

This study tests whether adding venetoclax to the standard chemotherapy before a stem cell transplant can help people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) stay cancer-free longer. About 138 patients aged 12 to 60 will be randomly assigned…

This program provides galinpepimut-S, an experimental immunotherapy, to individual patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have run out of standard treatment options. It is not a clinical trial but a way to access the drug when no other su…

This early-phase study tests whether adding the drug venetoclax to standard chemotherapy is safe and effective for adults with newly diagnosed acute myeloid leukemia (AML) or advanced myelodysplastic syndrome (MDS). About 99 participants will receive different doses of venetoclax…

This early-stage study tests whether adding two drugs, decitabine and venetoclax, to a standard stem cell transplant can make the treatment safer for people with high-risk blood cancers like leukemia. About 20 adults aged 18-75 with a matching donor will receive the new drug comb…

This early-stage study tests a new drug called iadademstat combined with a standard chemotherapy (azacitidine) for people with myelodysplastic syndrome (MDS), a bone marrow disorder. The main goal is to find the safest dose for future studies. About 12 adults with higher-risk MDS…

This study tests an experimental drug called elritercept (KER-050) in about 160 adults with a bone marrow disorder called myelodysplastic syndromes (MDS) who have anemia. The main goal is to check the drug's safety and find the best dose. Researchers will also see if it helps the…

This study is for people with serious blood cancers, immune deficiencies, or genetic disorders who need a stem cell transplant. Researchers are using umbilical cord blood from unrelated donors to see how well the new cells take hold and rebuild healthy blood counts. The goal is t…

This study looks at whether getting a stem cell transplant right away is as good as getting other treatments first and then the transplant for people with high-risk myelodysplastic syndrome (MDS). About 236 adults will be randomly assigned to one of two groups. The goal is to see…

This study tests a new way of giving two approved drugs (5-azacitidine and decitabine) to people with myelodysplastic syndromes (MDS) or related bone marrow disorders. Instead of standard high doses, the drugs are given in a low-dose, alternating schedule to reduce side effects a…

This study tests whether adding a specific type of donor cell (CD45RA-depleted) can help children recover their immune system faster after a stem cell transplant for blood cancers. The goal is to lower the risk of serious viral or fungal infections without increasing graft-versus…

This early-phase study tests whether specially engineered donor immune cells (TSC-100 or TSC-101) can safely prevent blood cancers like AML, MDS, or ALL from coming back after a stem cell transplant. About 75 adults will receive either the engineered cells or standard care. The m…

This study tests a treatment called Orca-T for people with acute myeloid leukemia or myelodysplastic syndrome. Orca-T is made from a donor's blood cells and given after a stem cell transplant. The goal is to see if it can help patients live longer without the cancer coming back a…

This study tests whether adding high-dose vitamin C to a standard chemotherapy drug (azacitidine) can help adults with a serious bone marrow disorder called myelodysplastic syndrome (MDS). About 38 people with higher-risk MDS will receive the combination intravenously. The goal i…

This study tests a drug called luspatercept in 40 adults with lower-risk myelodysplastic syndromes (MDS), a bone marrow condition that often requires frequent blood transfusions. The goal is to see if luspatercept can reduce the number of transfusions needed. Participants will re…

This study is for adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who have had a stem cell transplant from a half-matched donor. After the transplant, participants receive extra immune cells called natural killer (NK) cells from the same donor to try t…

This study tests a treatment for people with myelodysplastic syndromes (MDS), a bone marrow disorder. It combines a drug called venetoclax with a chemotherapy-like agent and an infusion of immune cells from a partially matched donor. The goal is to control the disease and improve…

This study tests a reduced-intensity chemotherapy combination (fludarabine, busulfan, melphalan) given before a stem cell transplant in people aged 55 and older with myeloid cancers like AML, MDS, or CMML. The goal is to see if this gentler approach can help patients stay free of…

This study tests a new experimental drug called EP0042 in adults with advanced blood cancers like acute myeloid leukemia (AML). The goal is to find a safe dose that might work against the cancer, either alone or with other treatments. About 70 participants will be enrolled to che…

This early-phase study tests a new way to do a stem cell transplant for people with aggressive or returning acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The method uses specially selected donor cells to try to prevent graft-versus-host disease without needing …

This early-phase study tests a new automated method (CliniMACS Prodigy) to select CD34 stem cells for patients with blood cancers who need a stem cell boost or second transplant. The goal is to reduce the risk of severe graft-versus-host disease (GVHD) while improving blood cell …

This study tests whether giving patients a fecal transplant (healthy donor stool) can prevent graft-versus-host disease, a serious complication where donor immune cells attack the patient's body after a stem cell transplant. About 150 adults with blood cancers like leukemia or ly…

This study tests whether giving blood transfusions at home is practical and acceptable for cancer patients who need regular transfusions. About 30 adults with blood cancers or bone marrow failure will receive 1-5 blood product units at home. Researchers will track how often trans…

This study looks at whether offering blood transfusions at home for people with advanced blood cancers who are in hospice care can improve their quality of life, mood, and reduce hospital visits near the end of life. About 700 adults with relapsed or hard-to-treat blood cancers w…

This study tests whether tranexamic acid (TXA), a drug that helps blood clots stay in place, can reduce bleeding in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). About 75 adults with these blood cancers who have low platelet counts will be randomly …

This study is for people with myelodysplastic syndromes (MDS) who are getting a stem cell transplant. Researchers want to see if measuring certain stem cells in the bone marrow can better predict if the disease will come back after transplant. About 163 participants will be follo…

This study looks at genetic changes in people with early-stage blood cancers or conditions that may lead to cancer. Researchers will analyze blood, bone marrow, or cheek cell samples from up to 10,000 participants to find DNA errors linked to cancer risk and progression. The goal…

This study collects blood, tissue, and body fluid samples from up to 15,000 people with blood cancers or related disorders. The samples are stored in a central lab for future research on diagnosis, prognosis, and immune monitoring. Participants do not receive any treatment as par…

This study looks at whether a new whole genome sequencing test called ChromoSeq can find more genetic changes in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) than standard tests. About 325 adults will have their blood or bone marrow tested with both …

This study follows people with a gene change (DDX41) that raises their risk for blood cancers like MDS and AML, along with their relatives. Researchers will collect health updates, blood samples, and medical records for up to 10 years to learn how the gene affects cancer developm…

This study is for children and teens with rare blood cancers called MDS and JMML. The goal is to make diagnoses more accurate by using a standard set of tests and looking closely at genetic changes. Researchers will track how patients do over time, including those who get a stem …

This study aims to learn more about myelodysplastic syndromes (MDS) by following people with the condition for up to 20 years. Researchers will collect blood, bone marrow, and other samples to better understand how MDS progresses. Up to 1,100 participants, including healthy donor…

This study looks at how services from Blood Cancer United (formerly The Leukemia & Lymphoma Society) affect people with blood cancers like leukemia, lymphoma, and myeloma. Researchers will track 400 patients over time to see if the organization helps with access to care, quality …

This study collects blood, bone marrow, skin, saliva, and stool samples from 1,000 healthy adults aged 18 and older. The samples are used as a comparison to better understand myelodysplastic syndromes (MDS), a group of blood disorders that can lead to cancer. Participants do not …

This study tests a telehealth program to help older adults (60+) with blood cancers like leukemia talk with their doctors about their care wishes. The goal is to see if it improves communication, reduces anxiety, and helps patients complete advance directives. About 207 patients …

This study looks at whether a new whole genome test called ChromoSeq can find genetic changes in people with myelodysplastic syndromes (MDS) as well as current standard tests. About 60 adults with MDS will provide samples, and doctors will compare results. The goal is to see if C…

This study looks at how the cancer drug ASTX727 (decitabine and cedazuridine) is processed by the body in people with severe kidney problems compared to those with normal kidneys. It involves 18 adults with certain blood cancers or solid tumors. The goal is to understand safety a…

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…

This study is gathering information from 2,000 people who are receiving a stem cell transplant for blood cancers or immune disorders. The goal is to track survival and complications over time to help doctors and researchers improve future treatments. No new drugs or procedures ar…

This study collects blood, bone marrow, and other samples from up to 1,716 people with non-cancerous blood diseases and their family members. Researchers will analyze genes to find causes of these diseases and why some people get sicker than others. The goal is to improve future …

This study looks at whether measuring certain proteins in the blood (called cytokines) can help predict how patients with acute myeloid leukemia or related blood cancers will do on a milder type of chemotherapy. Researchers will collect blood samples from 60 adults before and dur…

This study looks at how anemia affects brain function, especially thinking and memory. Researchers will use a non-invasive light-based brain scan (fNIRS) to measure brain activity in 323 adults with different types of anemia. The goal is to find which brain areas are affected and…